CBI

Leading life science success

CBI is Israel’s largest life sciences holding company

about cbi

Clal Biotechnology Industries (TASE: CBI) is Israel’s leading life sciences investment company. CBI supports life sciences by identifying and powering science backed ventures and proactively guiding them to transform the healthcare industry.

portfolio

The CBI portfolio is comprised of biotechnology and medical device companies developing breakthrough solutions for serious unmet medical needs, while offering substantial value and investment potential.

+

MediWound

MediWound (Nasdaq: MDWD) is a specialty biotechnology company focused on the fields of severe burn and chronic wound management.
+

Gamida Cell

Gamida Cell is a cell and immune therapy visionary. Lead product, NiCord® is currently in phase III clinical trial in hematological malignancies.
+

Anchiano (formerly Biocancell)

Anchiano Therapeutics (TASE: ANCN) is a clinical stage biopharmaceutical company dedicated to developing new therapies for non-muscle-invasive bladder cancer.
+

Elicio

Elicio develops platform technologies to deliver agents directly to the antigen-presenting cells of the lymph nodes with many potential applications in cancer
+

Neon Therapeutics

Neon Therapeutics (Nasdaq: NTGN) is a clinical stage, immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer.
+

Cadent Therapeutics

Cadent Therapeutics is developing novel drugs for neurological and psychiatric disorders.
+

Exithera

eXIthera Pharmaceuticals is a clinical stage biotech company focused on discovering and developing Factor XIa inhibitors for the prevention of stroke and thrombosis.
+

Biokine

Biokine Therapeutics is company focused on developing novel therapeutics to treat cancer. It's lead product, BL-8040, is licensed to BiolineRx and is in phase III clinical development.

See complete portfolio

Press Releases

2020

23

Jan

Biokine: BioLineRx Completes Recruitment into the Triple Combination Arm of the Motixafortide (BL-8040) COMBAT/KEYNOTE-202 Study in Metastatic Pancreatic Cancer
16

Jan

Neon Therapeutics: BioNTech to Acquire Neon to Strengthen Global Leadership Position in T Tell Therapies
16

Jan

Biokine: Motixafortide (BL-8040) Receives Orphan Drug Designation for the Treatment of Pancreatic Cancer in Europe
12

Jan

כינוס אסיפה כללית מיוחדת של בעלי מניות ביום ה’, 13 בפברואר 2020 ב- 14:30
07

Jan

Gamida Cell: Completion of Patient Enrollment into Omidubicel’s Phase III Clinical Study in Hematologic Malignancies in Need of Marrow Transplant
07

Jan

MediWound: BARDA Initiates the Procurement of NexoBrid for Emergency Response

Read all Press Releases